{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:33:58Z","timestamp":1793795638081,"version":"4.6.1"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["517043330"],"award-info":[{"award-number":["517043330"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL136389"],"award-info":[{"award-number":["R01HL136389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL163277"],"award-info":[{"award-number":["R01HL163277"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL131517"],"award-info":[{"award-number":["R01HL131517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL160992"],"award-info":[{"award-number":["R01HL160992"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL165704"],"award-info":[{"award-number":["R01HL165704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL164838"],"award-info":[{"award-number":["R01HL164838"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["965286"],"award-info":[{"award-number":["965286"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatment of resistant hypertension and pulmonary arterial hypertension, label expansions for bempedoic acid and semaglutide, and the results of major randomized clinical trials (RCTs) that have met the pre-specified primary endpoints, thereby filling some gaps in knowledge and opening new perspectives in the management of CVD, and those RCTs whose results did not confirm the proposed research hypotheses. We also include a section on drug safety, where we describe the newest data on adverse reactions and drug\u2013drug interactions that may complicate treatment and\/or reduce drug adherence with the consequent decrease in drug effectiveness. Finally, we present the most important ongoing phase 2 and phase 3 clinical trials assessing the efficacy and safety of cardiovascular drugs for the prevention and treatment of CVD.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf012","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:39:47Z","timestamp":1740472787000},"page":"292-317","source":"Crossref","is-referenced-by-count":15,"title":["New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"School of Medicine, Universidad Complutense, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n Department of Pharmacology and Toxicology, , Avenida Ram\u00f3n y Cajal s\/n, 28040 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Science, Oslo University , 0318 Oslo ,","place":["Norway"]},{"name":"Danderyd Hospital, Karolinska Institute Department of Clinical Sciences, , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"University of Perugia School of Medicine Department of Medicine and CERICLET, , 06156 Perugia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"University of Bologna-IRCCS AOU S. Orsola Department of Cardiovascular Medicine, , 40138 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Section of Pharmacology and Toxicology, University of Florence Department Neurofarba, , 50121 Firenze ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe A","family":"Dan","sequence":"additional","affiliation":[{"name":"Carol Davila. University of Medicine, Academy of Romanian Scientist , Bucharest, Sector 2 ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT) , 6800 Feldkirch ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Semmelweis University Department of Pharmacology and Pharmacotherapy, , Budapest, H-1089 ,","place":["Hungary"]},{"name":"Pharmahungary Group , Szeged H-6722 ,","place":["Hungary"]},{"name":"Center for Pharmacology and Drug Research & Development, Semmelweis University , Budapest, H-1089 ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital Department of Cardiology, , Aarhus 8200 ,","place":["Denmark"]},{"name":"Faculty of Health, Aarhus University Department of Clinical Medicine, , Aarhus 8200 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Klingenberg","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart and Thorax Center Department of Cardiology, , 61231 Bad Nauheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"ciTechCare\u2014Center for Innovative Care and Health Technology, Polytechnic University of Leiria , 2414-016 Leira ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Parker","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Sheffield , Sheffield S5 7AU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"LUM University Department of Medicine and Surgery, , 70010 Casamassima, Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-0099","authenticated-orcid":false,"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Medical University of Vienna Department of Medicine, , 1090 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"Preventive Cardio-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital , 0370 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Cardiology and Angiology, Justus-Liebig-University , Giessen ,","place":["Germany"]},{"name":"Kerckhoff-Clinic\/DZHK Department of Cardiology, , 61231 Bad Nauheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-0189","authenticated-orcid":false,"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St. George's, University of London , Cranmer Terrace, London SW17 0RE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen , 45122 Essen ,","place":["Germany"]},{"name":"Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al Department of Medicine, , Montr\u00e9al, Quebec H1T 1C8 ,","place":["Canada"]},{"name":"Baylor College of Medicine Department of Integrative Physiology, , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2025062507105076200_bib1","doi-asserted-by":"crossref","first-page":"i","DOI":"10.1517\/14656566.2014.906940","article-title":"Is being the first ever \u2018better\u2019 than being the best?","volume":"15","author":"Luscombe","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2025062507105076200_bib2","first-page":"371","article-title":"After 30 years, the first endothelin-receptor antagonist (aprocitentan) is approved for the treatment of arterial hypertension","volume":"10","author":"Tamargo","year":"2024"},{"key":"2025062507105076200_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"2025062507105076200_bib4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025062507105076200_bib5","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-024-02058-9","article-title":"Sotatercept: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"2025062507105076200_bib8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025062507105076200_bib12","doi-asserted-by":"crossref","first-page":"e010685","DOI":"10.1161\/CIRCOUTCOMES.123.010685","article-title":"Association of use and dose of lipid-lowering therapy post acute myocardial infarction with 5-year survival in older adults","volume":"17","author":"Fayol","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025062507105076200_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u2018inclisiran first\u2019 Strategy vs usual care in patients with atherosclerotic cardiovascular disease","author":"Koren","year":"2024;","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib14","doi-asserted-by":"crossref","first-page":"e209173","DOI":"10.1212\/WNL.0000000000209173","article-title":"Statin therapy for secondary prevention in ischemic stroke patients with cerebral Microbleeds","volume":"102","author":"Prats-Sanchez","year":"2024","journal-title":"Neurology"},{"key":"2025062507105076200_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib17","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib19","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib20","first-page":"e013242","article-title":"Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"16","author":"Kuno","year":"2023","journal-title":"Circ: Cardiovasc Interv"},{"key":"2025062507105076200_bib21","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial","volume":"9","author":"Li","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025062507105076200_bib23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025062507105076200_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"2025062507105076200_bib25","doi-asserted-by":"crossref","first-page":"e075707","DOI":"10.1136\/bmj-2023-075707","article-title":"Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial","volume":"385","author":"Zhu","year":"2024","journal-title":"BMJ"},{"key":"2025062507105076200_bib26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"2025062507105076200_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for Factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib28","first-page":"353","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023"},{"key":"2025062507105076200_bib29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025062507105076200_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib33","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib37","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","author":"Rodriguez","year":"2024;","journal-title":"JAMA Intern. Med."},{"key":"2025062507105076200_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.124.069808","article-title":"Effect of colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography: the COLOCT randomized clinical trial","volume":"150","author":"Yu","year":"2024","journal-title":"Circulation"},{"key":"2025062507105076200_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/dc23-1825","article-title":"Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"47","author":"Roubille","year":"2024","journal-title":"Diabetes Care"},{"key":"2025062507105076200_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"2025062507105076200_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib50","article-title":"Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","author":"Vaduganathan","year":"2024;","journal-title":"JAMA Cardiol"},{"key":"2025062507105076200_bib51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"2025062507105076200_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2025062507105076200_bib53","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","author":"Packer","year":"2024;","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib54","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120\u00a0mm Hg versus less than 140\u00a0mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib56","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib57","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2024.8771","article-title":"Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS randomized clinical trial","volume":"332","author":"Devereux","year":"2024","journal-title":"JAMA"},{"key":"2025062507105076200_bib59","doi-asserted-by":"crossref","first-page":"e013227","DOI":"10.1161\/JAHA.119.013227","article-title":"Atrial cardiopathy in the absence of atrial fibrillation increases risk of ischemic stroke, incident atrial fibrillation, and mortality and improves stroke risk prediction","volume":"9","author":"Edwards","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025062507105076200_bib60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"key":"2025062507105076200_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib62","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/CIRCULATIONAHA.124.069606","article-title":"Topical versus intravenous tranexamic acid in patients undergoing cardiac surgery: the DEPOSITION randomized controlled trial","volume":"150","author":"Lamy","year":"2024","journal-title":"Circulation"},{"key":"2025062507105076200_bib63","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","article-title":"Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction","volume":"390","author":"Gibson","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib64","doi-asserted-by":"crossref","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evidence"},{"key":"2025062507105076200_bib65","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jchf.2022.02.008","article-title":"Acute decompensated heart failure in the setting of acute coronary syndrome","volume":"10","author":"Harrington","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025062507105076200_bib66","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib67","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2025062507105076200_bib68","doi-asserted-by":"crossref","first-page":"e079061","DOI":"10.1136\/bmj-2023-079061","article-title":"Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial","volume":"385","author":"Li","year":"2024","journal-title":"BMJ"},{"key":"2025062507105076200_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of Vascular Recurrent Events in Non-Cardioembolic Stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly","year":"2024","journal-title":"Lancet"},{"key":"2025062507105076200_bib70","article-title":"Colchicine in acute myocardial infarction","author":"Jolly","year":"2025;","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib71","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2024.01.002","article-title":"Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI","volume":"83","author":"Mann","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.17123","article-title":"Continuation vs discontinuation of renin-angiotensin system inhibitors before major noncardiac surgery: the stop-or-not randomized clinical trial","author":"Legrand","year":"2024;","journal-title":"JAMA"},{"key":"2025062507105076200_bib73","article-title":"Routine spironolactone in acute myocardial infarction","author":"Jolly","year":"2025;","journal-title":"N Engl J Med"},{"key":"2025062507105076200_bib74","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"key":"2025062507105076200_bib76","first-page":"1863","article-title":"Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis","volume":"31","author":"Dinu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025062507105076200_bib77","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"key":"2025062507105076200_bib78","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation: a nationwide cohort study","volume":"177","author":"Simon","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025062507105076200_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2016.08.017","article-title":"Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies","volume":"118","author":"Laporte","year":"2017","journal-title":"Pharmacol Res"},{"key":"2025062507105076200_bib80","doi-asserted-by":"crossref","first-page":"e243208","DOI":"10.1001\/jamanetworkopen.2024.3208","article-title":"Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding","volume":"7","author":"Rahman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025062507105076200_bib81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/eurheartj\/ehae736","article-title":"Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study","volume":"46","author":"Petersen","year":"2025","journal-title":"Eur Heart J"},{"key":"2025062507105076200_bib82","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2025062507105076200_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"2025062507105076200_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jacc.2023.10.041","article-title":"Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors","volume":"83","author":"Trolle Lagerros","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025062507105076200_bib85","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","article-title":"Risk of stroke and myocardial infarction among initiators of triptans","volume":"81","author":"Petersen","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025062507105076200_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf012\/62352529\/pvaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/3\/292\/62352529\/pvaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/3\/292\/62352529\/pvaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:11:07Z","timestamp":1750835467000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/3\/292\/8064771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,8]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf012","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,8]]}}}